57 Recruiting Non-Hodgkin Lymphoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Non-Hodgkin Lymphoma
Related Conditions
Top Recruiting Non-Hodgkin Lymphoma Studies
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 City of Hope Cancer Center — Duarte, California
View Study & Checklist ➔A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
📍 The University of Arizona Cancer Center - North Campus /ID# 242219 — Tucson, Arizona
View Study & Checklist ➔A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
📍 Infirmary Cancer Care — Mobile, Alabama
View Study & Checklist ➔AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
📍 University of Chicago — Chicago, Illinois
View Study & Checklist ➔Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
📍 UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program — San Francisco, California
View Study & Checklist ➔A Rollover Study of CC-122
📍 Local Institution - 100 — New York, New York
View Study & Checklist ➔A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
📍 Lucile Packard Children's Hospital /ID# 240854 — Palo Alto, California
View Study & Checklist ➔BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
📍 Taussig Cancer Institute | Cleveland Clinic — Cleveland, Ohio
View Study & Checklist ➔Lazarus: IT Therapy for ICANS
📍 Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View Study & Checklist ➔Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
📍 Houston Methodist Hospital — Houston, Texas
View Study & Checklist ➔A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Amping up With PemJAK
📍 Columbia University Irving Medical Center — New York, New York
View Study & Checklist ➔Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
📍 Local Institution - 0016 — Portland, Oregon
View Study & Checklist ➔Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
View Study & Checklist ➔CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
📍 New York Medical College — Valhalla, New York
View Study & Checklist ➔Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
📍 Uniformed Services University of the Health Sciences — Bethesda, Maryland
View Study & Checklist ➔Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
📍 University of Alabama — Birmingham, Alabama
View Study & Checklist ➔Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
📍 Natera, Inc. — Austin, Texas
View Study & Checklist ➔In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Auto Stem Cell Transplant for Lymphoma Patients
📍 Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
View Study & Checklist ➔Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
📍 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
📍 University of Colorado Hospital — Aurora, Colorado
View Study & Checklist ➔